论文部分内容阅读
目的本文调查前列腺癌的影像学和非手术保守治疗的现状,从而确定前列腺癌体外放疗(EBRT)后复发影像学表现的影响。方法系统分析截止至2012年Medline上的相关文献,并根据专家组作者的推荐增加其他的文献。结果 EBRT越来越多地用于前列腺癌的治疗。对于放疗后复发的前列腺癌,非手术的保守治疗正从研究阶段转为治疗选择方案。因此,一些专业学会制定了这些保守治疗措施的指南,包括临床和影像学适应证,甚至疗程、有效性和长期的不良反应。在一些研究中,准确确定肿瘤的部位和范围对于选择靶病灶和确定合适的治疗病人是至关重要的。但是,越来越多的研究者意识到基于测量大小的解剖学方法存在着很多局限性,特别是对于放疗后继续增长或复发的活动性不明确的肿瘤。结论到目前为止,影像学的创新点主要集中于将良好的解剖学分辨力与代表特定代谢过程或肿瘤水平的特异性生物标志物相结合。新的分子标记物的出现,能够促进直接确定肿瘤存在方法的发展,提高肿瘤的检出率。
Purpose This study investigated the status of imaging and non-surgical conservative treatment of prostate cancer to determine the effect of recurrence imaging after prostate cancer radiotherapy (EBRT). Methods Systematic analysis of relevant literature on Medline up to 2012 and additional literature based on the recommendations of panelists. Results EBRT is increasingly used in the treatment of prostate cancer. For prostate cancer recurrence after radiotherapy, non-surgical conservative treatment is being transferred from the research phase to treatment options. Therefore, some professional societies have developed guidelines for these conservative treatments, including clinical and radiological indications, and even medications, efficacy and long-term adverse effects. In some studies, accurately locating the site and extent of the tumor is crucial for selecting the target lesion and for identifying the appropriate patient to be treated. However, more and more researchers are aware of the limitations of anatomic methods based on measurement size, especially for those with undefined activity that continue to grow or recur after radiotherapy. Conclusion So far, the innovation of imaging has focused on combining good anatomic resolution with specific biomarkers that represent specific metabolic processes or tumor levels. The emergence of new molecular markers can promote the direct determination of the existence of tumor and improve the detection rate of tumors.